SAB Biotherapeutics Inc. (SABSW)
0.03
-0.00 (-3.23%)
At close: Feb 28, 2025, 3:59 PM
SAB Biotherapeutics Balance Sheet Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Cash & Equivalents | 56.57M | 15.05M | 33.21M | 12.61M | 6.35M |
| Short-Term Investments | n/a | n/a | n/a | n/a | n/a |
| Long-Term Investments | n/a | n/a | n/a | n/a | n/a |
| Other Long-Term Assets | 350.23K | 467.69K | n/a | n/a | n/a |
| Receivables | n/a | 5.56M | 8.01M | 20.57M | 2.82M |
| Inventory | n/a | n/a | n/a | n/a | n/a |
| Other Current Assets | 2.34M | 1.49M | 8.97M | 1.28M | 124K |
| Total Current Assets | 58.91M | 22.1M | 48.42M | 34.46M | 9.29M |
| Property-Plant & Equipment | 24.68M | 28.34M | 30.95M | 22.08M | 8.71M |
| Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 25.03M | 28.81M | 30.95M | 22.08M | 8.71M |
| Total Assets | 83.94M | 50.9M | 79.37M | 56.54M | 18M |
| Account Payables | 945.93K | 3.68M | 4.46M | 7.38M | 2.17M |
| Deferred Revenue | 1.32M | n/a | 100K | 100K | n/a |
| Short-Term Debt | 1.85M | 2.02M | 3.1M | 1.66M | 1.95M |
| Other Current Liabilities | 6.65M | 9.24M | 16.81M | 1.92M | -4.12M |
| Total Current Liabilities | 10.81M | 14.99M | 24.68M | 11.06M | 4.62M |
| Long-Term Debt | 4.05M | 4.53M | 5.42M | 6.47M | 53.45K |
| Other Long-Term Liabilities | 11.77M | 320.93K | 10.72M | n/a | 15.64M |
| Total Long-Term Liabilities | 15.83M | 4.85M | 16.14M | 6.47M | 15.69M |
| Total Liabilities | 26.64M | 19.85M | 40.82M | 17.53M | 20.31M |
| Total Debt | 5.91M | 5.93M | 6.74M | 8.13M | 7.64M |
| Common Stock | 929.00 | 5.09K | 4.35K | 3.52K | 3.52K |
| Retained Earnings | -90.06M | -47.87M | -29.13M | -11.98M | -32.1M |
| Comprehensive Income | 26.42K | n/a | n/a | n/a | n/a |
| Shareholders Equity | 57.3M | 31.06M | 38.55M | 39.01M | -2.31M |
| Total Investments | n/a | n/a | n/a | n/a | n/a |